Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside

HCV Polymerase Inhibitor Being Presented at AASLD

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, California, from October 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor.

ANA598 Phase I Study Results

In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. All reported adverse events were classified as mild or moderate, with no apparent dose relationship and no pattern of events within any body system. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of 24 to 30 hours in the fasted state and 22 hours in the fed state, consistent with the potential for once-daily or twice-daily oral dosing. In the cohort that received two 800 mg
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... NEW YORK , May 6, 2015  The ... ("GEVA" or the "Company") by Alexion Pharmaceuticals, Inc. ("Alexion") ... action, shareholder rights law firm, for possible breaches of ... Board of Directors of GEVA for agreeing to sell ... Company announced a definitive agreement for Alexion to acquire ...
(Date:5/6/2015)... Inc. (NASDAQ: SQNM ), a life sciences company committed ... and services, today reported total revenues of $37.8 million for ... to revenues of $37.1 million for the first quarter of ... $0.12 per share, basic and $0.11 per share, diluted, for ... $15.7 million, or $0.13 per share, basic and diluted, for ...
(Date:5/6/2015)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... 31, 2015. "The first quarter of 2015 ... HETLIOZ and Fanapt.  As we are just at the ... U.S., the growth potential for HETLIOZ remains ahead.  Similarly, ... potential of this product through the coming decade and ...
Breaking Medicine Technology:WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 2Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 3Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 4Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 5Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 6Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 7Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 8Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 9Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 10Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 11Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 12Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 12
... Group Inc. (Nasdaq: WWIN ) ("Winner Medical" or ... medical dressings and consumer products made from 100% cotton, today ... September 30, 2011. Fiscal ... 30.3% to $149.9 million from $115.0 million in the prior ...
... 2011  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... authorized generic version of LIPITOR® (atorvastatin calcium ... Inc.  Watson began shipping the product today.  LIPITOR® ... reduce elevated total cholesterol, LDL, triglycerides and to increase ...
Cached Medicine Technology:Winner Medical Reports Full Fiscal Year 2011 Results 2Winner Medical Reports Full Fiscal Year 2011 Results 3Winner Medical Reports Full Fiscal Year 2011 Results 4Winner Medical Reports Full Fiscal Year 2011 Results 5Winner Medical Reports Full Fiscal Year 2011 Results 6Winner Medical Reports Full Fiscal Year 2011 Results 7Winner Medical Reports Full Fiscal Year 2011 Results 8Winner Medical Reports Full Fiscal Year 2011 Results 9Winner Medical Reports Full Fiscal Year 2011 Results 10Winner Medical Reports Full Fiscal Year 2011 Results 11Winner Medical Reports Full Fiscal Year 2011 Results 12Winner Medical Reports Full Fiscal Year 2011 Results 13Winner Medical Reports Full Fiscal Year 2011 Results 14Winner Medical Reports Full Fiscal Year 2011 Results 15Winner Medical Reports Full Fiscal Year 2011 Results 16Winner Medical Reports Full Fiscal Year 2011 Results 17Watson Launches Generic LIPITOR® 2Watson Launches Generic LIPITOR® 3
(Date:5/6/2015)... FL (PRWEB) May 06, 2015 Qushanna Doby ... outside a nearby drug treatment center in Florida while under ... on May 4th. New surveillance tapes released by CBS4’s Peter ... without her baby. Doby’s child is around one year old. ... crying and shivering outside was not named. The residents polled ...
(Date:5/6/2015)... 05, 2014 (PRWEB) May 06, 2015 ... accepted, on behalf of MEBC, an Alliance Award ... JDA Software during FOCUS 2015, JDA’s annual user ... the manufacturing, retail and wholesale distribution sectors. This ... their clients are receiving services that advance their ...
(Date:5/6/2015)... Baltimore, MD (PRWEB) May 06, 2015 The ... Baltimore Ravens for the 6th annual charity softball ... 7:00pm at M & T Bank Stadium. Past years guests ... among others. Tickets are still on sale if ... been advocating for local non-profit organizations, such as SOAR ...
(Date:5/6/2015)... Jacksonville, Fla. (PRWEB) May 06, 2015 ... Orthopaedic Institute are the first in north Florida ... This technology is the latest innovation in total ... a highly advanced, surgeon-controlled robotic arm that enables ... Baptist Medical Center Jacksonville has offered MAKOplasty® partial ...
(Date:5/6/2015)... of Prussia, PA (PRWEB) May 06, 2015 ... Process Outsourcing solutions to the Medicare Advantage, Medicare Part ... finalists in the Continuity and Resilience Team category at ... the Business Continuity Institute to recognize the outstanding contribution ... operating in the North America Region, including the USA ...
Breaking Medicine News(10 mins):Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... PITTSBURGH , Feb. 12 Pittsburgh ... free antibiotics program in September of 2009, and is pleased ... $3 million in free prescriptions for customers in ... 590,000 prescriptions for free antibiotics have been filled by the ...
... , World-Renowned Policy Experts Held International ... , Global Town Hall Discussed How to Feed ... , WASHINGTON , Feb. 12 ... blizzard today to identify solutions for the greatest agricultural challenges of ...
... NEW YORK , Feb. 12 Dr. Jennifer Muller ... as the 2009 Veterinarian of the Year by Summit VetPharm® at the ... Show Dogs of the Year ® Awards, presented by Dogs In ... a leader in efforts to improve living conditions and strengthen regulations at ...
... , SHANGHAI , Feb. 12 ... of nutritional products, announced today that it, together with its parent ... strategic partnership with Bright Food (Group) Co., LTD (Bright Food). The ... ,s nutritional products market. Bright Food , a leading state-owned ...
... 12, 2010Hypnosis has potential therapeutic value in children with ... or unexplained sensations of difficulty breathing and for lessening ... hypnosis as an adjunct to conventional treatment and its ... physiological changes are explored in a provocative paper in ...
... than ,typical, flu season , FRIDAY, Feb. 12 (HealthDay News) ... federal health officials said Friday that about 57 million Americans ... total could range as high as 84 million. , In ... estimates that as many as 378,000 people were hospitalized due ...
Cached Medicine News:Health News:Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions 2Health News:Now Serving 9 Billion: A Global Town Hall 2Health News:Now Serving 9 Billion: A Global Town Hall 3Health News:Now Serving 9 Billion: A Global Town Hall 4Health News:Dr. Jennifer Muller Named Veterinarian of the Year 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Hypnosis can relieve symptoms in children with respiratory diseases 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 3
... the "Consensus Concept" approach to design by ... of a Scientific Advisory Board. The result ... state-of-the-art features. Consensus Knee implants are designed ... and allow near normal kinematics. The components ...
The major innovations in posterior stabilized (PS) knee design....
The GENESIS II* Total Knee System will define the state of knee implants....
... system's curved-on-curved articulation maintains full inter-changeability. ... options for better patient fit. The ... spray porous coating, which offers an ... processed polyethylene is used for consistent, ...
Medicine Products: